

*許勝傑助理教授

所有發表期刊論文

1. **Hsu SC**, Yan BS, Pan JM, Syu WJ. A monoclonal antibody reacts with maltose-binding protein of Escherichia coli and related enteric bacteria. 1997 May. *J. Immunol. Methods* 204:169-74.
2. Lin HP, **Hsu SC**, Wu JC, Sheen IJ, Yan BS, Syu WJ. Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies. 1999 Jan. *J. Gen. Virol.* 80:91-6.
3. **Hsu SC**, Lin HP, Wu JC, Ko KL, Sheen IJ, Yan BS, Chou CK, Syu WJ. Characterization of a strain-specific monoclonal antibody to hepatitis delta virus antigen. 2000 Jun. *J. Virol. Methods* 87(1-2):53-62.
4. Huang YH, Wu JC, Tao MH, Syu WJ, **Hsu SC**, Chi WK, Chang FY, Lee SD. DNA-based immunization produces Th1 immune responses to hepatitis delta virus in a mouse model. 2000 Jul. *Hepatology* 32:104-10.
5. **Hsu SC**, Syu WJ, Ting LT, Wu JC. Immunohistochemical differentiation of hepatitis D virus genotypes. 2000 Nov. *Hepatology* 32:1111-6.
6. Chuang CH, **Hsu SC**, Hsu CL, Hsu TC, Syu WJ. Construction of a tagging system for subcellular localization of proteins encoded by open reading frames. 2001 Mar-Apr. *J. Biomed. Sci.* 8:170-5.
7. **Hsu SC**, Syu WJ, Sheen IJ, Liu HT, Jeng KS, Wu JC. Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications. 2002 Mar. *Hepatology* 35:665-72.
8. Huang YH, Wu JC, **Hsu SC**, Syu WJ. Varied immunity generated in mice by DNA vaccines with large and small hepatitis delta antigens. 2003 Dec. *J. Virol.* 77(24):12980-5.
9. **Hsu SC**, Wu JC, Sheen IJ, Syu WJ. Interaction and replication activation of genotype I and II hepatitis delta antigens. 2004 Mar. *J. Virol.* 78(6):2693-700.
10. Wu JC, **Hsu SC**, Wang SY, Huang YH, Sheen IJ, Shih HH, Syu WJ. "Defective" mutations of hepatitis D viruses in chronic hepatitis D patients. 2005 Mar. *World J Gastroenterol.* 11(11):1658-62.
11. Lo HW, **Hsu SC**, Ali-Seyed M., Gunduz M, Xia W, Wei Y, Bartholomeusz G., Shih JY, Hung MC. Nuclear interaction of EGFR and STAT3 in the activation of iNOS/NO pathway. 2005 Jun. *Cancer Cell* 7(6):575-89.
12. Chuang CH, Chiu HJ, **Hsu SC**, Ho JY, Syu WJ. Comparison of Tir from enterohemorrhagic and enteropathogenic Escherichia coli strains: two

- homologues with distinct intracellular properties. 2006 Jan. J. Biomed. Sci. 1:73-87.
13. Lo HW, **Hsu SC**, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. 2006 Feb. Breast Cancer Res. Treat. 95(3):211-8. Review
 14. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, **Hsu SC**, Hung MC. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J. Cell. Biochem. 2006 Aug. 15. 98(6):1570-83.
 15. **Hsu SC** and Hung MC. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. 2007 Apr 6. J Biol. Chem. 282(14):10432-40.
 16. Lo WH, **Hsu SC**, Xia W, Cao X, Shih JY, Abbruzzese JL, Hortobagyi GN, Hung MC. Epidermal growth factor receptor cooperates with signal transducer and activator 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of *TWIST* gene expression. 2007 Oct. 1. Cancer Res. 67(19): 9066-76.
 17. **Hsu SC**, Miller SA, Wang Y, Hung MC. Nuclear EGFR is required for cisplatin resistance and DNA repair. Am. J. Transl. Res. 2009 Mar 8. 1(3):249-58.
 18. Huo L, Wang YN, Xia W, **Hsu SC**, Lai CC, Li LY, Chang WC, Wang Y, Hsu MC, Yu YL, Huang TH, Ding Q, Chen CH, Tsai CH, Hung MC. 2010 Sep 14. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc. Natl. Acad. Sci. 107(37):16125-30.
 19. Song H, Li CW, Labaff AM, Lim SO, Li LY, Kan SF, Chen Y, Zhang K, Lang J, Xie X, Wang Y, Huo LF, **Hsu SC**, Chen X, Zhao Y, Hung MC. 2011 Jan. 7 Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 404(1):68-73.
 20. Huang CR, Wang RY, **Hsu SC**, Lo SJ. 2012 Dec. Lysine-71 in the large delta antigen of hepatitis delta virus clade 3 modulates its localization and secretion. Virus Res. 170:75-84.
 21. Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV, **Hsu SC**. 2013 Feb. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol. 85:325-334.
 22. Yang HW, Lu YJ, Lin KJ, **Hsu SC**, Huang CY, She SH, Liu HL, Lin CW, Xiao MC, Wey SP, Chen PY, Yen TC, Wei KC, Ma CC. 2013 Sep. EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy. Biomaterials 34(29):7204-14.
 23. Liang SL, **Hsu SC**, Pan JT. 2014 May. Involvement of dopamine D2 receptor

in the diurnal changes of tuberoinfundibular dopaminergic neuron activity and prolactin secretion in female rats. *J Biomed Sci.* 21(1):37.